Jan 26,2023

AI Analysis of Cancer Mutations may Improve Therapy

Cancer has many faces - no wonder, then, that the range of cancer-causing mutations is huge as well. The totality of such genomic alterations in an individual is what experts call a "mutational landscape." These landscapes differ from one another depending on the type of cancer. Somatic structural variants (SVs) have been shown to account for more than half of all cancer-driving mutations. These are those mutations in cells that emerge over the course of life. Although somatic SVs play a crucial role in cancer development, relatively little is known about them. That's changing thanks to new research findings, which Dr. Ashley Sanders's recently published in the journal Nature Biotechnology along with the European Molecular Biology Laboratory (EMBL). "We developed a computational analysis method to detect and identify the functional effects of somatic SVs," she reports. This enabled the team to understand the molecular consequences of individual somatic mutations in different leukemia patients, giving them new insights into the mutation-specific alterations. Sanders says it may also be possible to use these findings to develop therapies that target the mutated cells, adding that “they open up exciting new avenues for personalized medicine."

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Aetion Collaborates With FDA to Explore Oncology RWD for Regulatory Science Research

Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced a five-year research collaboration with the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) to advance research using novel oncology real-world data (RWD) sources through platform analytics on the Aetion Evidence Platform® (AEP). Through this research collaboration, Aetion and the FDA will use the AEP to identify and analyze fit-for-purpose RWD sources to address key research questions that are relevant to prevention, clinical care, diagnostics, and treatment, in oncology. The research objectives include assessing real-world endpoints, evaluation of causal inference methods, and measuring and understanding health disparities to advance health equity.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 23,2023

A Blood Test for Cancer Shows Promise Thanks to Machine Learning

A team of researchers at the University of Wisconsin­-Madison has successfully combined genomics with machine learning in the quest to develop accessible tests that allow earlier detection of cancer. In a study published this week in Science Translational Medicine and led by Muhammed Murtaza, professor of surgery at the UW School of Medicine and Public Health, researchers used a machine-learning model to examine blood plasma for DNA fragments from cancer cells. The technique, which uses readily available lab materials, detected cancers at an early stage among most of the samples they studied.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 13,2023

AI Tool Developed to Predict Risk of Lung Cancer

As rates of lung cancer climb among non-smokers, new strategies are needed to screen and accurately predict lung cancer risk across a wider population. A study led by investigators from the Mass General Cancer Center, a member of Mass General Brigham, in collaboration with researchers at the Massachusetts Institute of Technology (MIT), developed and tested an artificial intelligence tool known as Sybil. Based on analyses of Low-dose chest computed tomography (LDCT) scans from patients in the U.S. and Taiwan, Sybil accurately predicted the risk of lung cancer for individuals with or without a significant smoking history. Results are published in the Journal of Clinical Oncology.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

ConcertAI and Caris Life Sciences Form Broad Partnership Creating Industry-Leading Molecular Oncology Research Platform to Accelerate Drug Development and Novel Research

ConcertAI and and Caris Life Sciences®(Caris), the leading molecular science, artificial intelligence (AI) and machine learning technology company announced a unique partnership to align the two companies' oncology capabilities. The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research. While detailed partnership terms have not been disclosed, as part of the partnership, the two organizations will also align their scientific talent and AI SaaS technologies to the research objectives of their academic and biopharma partners.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

FDA says yes to MedCognetics breast cancer screening AI

Digital health company MedCognetics has picked up an FDA approval for QmTRIAGE, its artificial intelligence-powered software for detecting breast cancer in medical images. The company said QmTRIAGE can help alleviate a chronic shortage in radiology services around the world. Dallas-based MedCognetics says the cloud-based AI software as a service (SaaS) has been trained on a diverse patient dataset harvested from around the world to reduce data bias, and can detect the earliest manifestations of cancer in all ethnicities. It slots into the standard radiology workflow, so the radiologist does not have to engage in any additional tasks during the process, with the AI's findings layered on top of mammography images.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 30,2022

Siemens Healthineers, Atrium Health Enter Multi-Year Value Partnership to Improve Health Care Capabilities, Access and Equity

Siemens Healthineers and Atrium Health, a leading nonprofit health provider known for its top-ranked pediatric, cancer and heart care programs, have announced a multi-year Value Partnership(1) agreement. This strategic agreement will focus on driving access to care in Atrium Health's service region across the southeastern U.S., improving health equity and enhancing economic mobility. Atrium Health will purchase more than $140 million in Siemens Healthineers devices and equipment, including advanced imaging technology, radiation oncology and precision endovascular robotics.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 20,2022

Reimagine Care and The Center for Cancer & Blood Disorders Announce Partnership

Reimagine Care announced today that it has partnered with The Center for Cancer & Blood Disorders (CCBD), one of the country's most respected cancer centers, to offer its home-based supportive care and symptom management program to patients in the Dallas-Fort Worth market. Thousands of CCBD patients will have access to on-demand support from experienced oncology nurses and advanced practitioners via text, phone, and video, along with in-home care when appropriate. The Reimagine Care program also alleviates much of the triage and symptom management demands on CCBD clinicians – improving provider wellbeing and increasing clinical capacity.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 03,2022

Philips Advances MR Radiotherapy Imaging and Simulation for Head and Neck Cancers

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company's artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received FDA 510(k) clearance and is commercially available in the U.S.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Notable Labs and VBL Therapeutics Merger Generates $10 Million Funding

VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, and Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced they have entered into a definitive merger agreement. Concurrent with the execution of the merger agreement, a healthtech-focused investor syndicate, including existing Notable stockholders Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund, have entered into a definitive securities purchase agreement with Notable to invest $10.3 million in gross proceeds prior to the close of the proposed merger. After completion of the merger, the combined company is expected to be capitalized with a cash runway into 2025.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news